Global Disease Challenges

hile the world continues to face ongoing challenges with HIV and tuberculosis, and many unknown and emerging threats, there is also an increasing shift in burden of disease toward noncommunicable diseases (NCDs) and mental health. At Johnson & Johnson, we are passionate about our work to save and improve people’s lives. We forge partnerships and identify new ways to pioneer human ingenuity to accelerate the development of new drug regimens, support the strengthening of healthcare systems and break down barriers to access in resource-limited settings.

Global Disease Challenges

expand

Our Aspiration: A world where innovations and holistic health solutions prevent, control and eliminate global disease challenges and epidemics.

5-Year Target: 175 million individuals will have benefited from Johnson & Johnson solutions that prevent, control and eliminate global diseases.

Status: Exceeded

Our Impact:

• How Johnson & Johnson Is Helping Tackle a Devastating Tropical Disease That Impacts Kids

• Working to Make HIV History

• Our Mission: Enabling a World Without TB

Related Content

Developing a Vaccine for COVID-19

ON NOW

New Pediatric Formulation of Janssen’s Treatment for Intestinal Worms Achieves World Health Organization Prequalification

ON NOW

“I Was on the Ground During the HIV Epidemic": Meet the Scientist Who's Sharing the Spotlight With Celebs at the Global Citizen Festival

ON NOW

Dr. Paul Stoffels, Johnson & Johnson Chief Scientific Officer, at 2017 Global Citizen Festival

Ending MDR-TB: “It’s Doable. Let’s Solve It”

ON NOW

The Global Fund, Stop TB, The Economist and WEF joined Johnson & Johnson in the coLaboratory for the Future

Johnson & Johnson Announces Partnership with CSIR-IMTECH to Develop Innovative New Tuberculosis Treatments

ON NOW

The New Ebola Clinical Trial That's Focused on Helping Halt Future Outbreaks

ON NOW

5 Ways Johnson & Johnson Is on the Fast Track to Helping End AIDS

ON NOW

U.S. FDA Approves Vermox™ Chewable (Mebendazole) For Treatment of Children and Adults With Roundworm and Whipworm Infections

ON NOW

mhNOW: How Entrepreneurs, Companies and Organizations Are Coming Together to Improve Mental Health

ON NOW

Unseen Enemy: The New Film That Looks at Why Viruses Like Zika, Ebola and Influenza Are So Prevalent

ON NOW

Johnson & Johnson Teams Up With Health Officials Across Brazil to Fight Zika

ON NOW

The Janssen Pharmaceutical Companies of Johnson & Johnson Partner on an Ambitious Tuberculosis Program in India

ON NOW

Our 2030 Promise

Johnson & Johnson has signed up to the 2030 UN Sustainable Development Goals—the world’s road map for progress.

Learn More About Our SDG Commitment

More From Johnson & Johnson

Innovation

The COVID-19 Data Plan: 3 Innovative Ways Johnson & Johnson Is Using Data Science to Fight the Pandemic

Tracking the spread of the virus in real time. Analyzing data to learn more about who's most vulnerable. These are just a couple of ways the company's data science team is helping inform how to respond to the pandemic.

ON NOW

Innovation

COVID-19 Update: Your Latest Questions About Johnson & Johnson's Investigational Vaccine Candidate Answered

With its Phase 3 clinical trial now fully enrolled, the Global Head of Research & Development at Janssen brings us up to speed on the progress of the company's vaccine candidate, including upcoming key milestones.

ON NOW